Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$139.03 USD
+2.50 (1.83%)
Updated Dec 26, 2024 04:00 PM ET
After-Market: $139.09 +0.06 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
NBIX 139.03 +2.50(1.83%)
Will NBIX be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NBIX
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Other News for NBIX
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neurocrine (NBIX) and Amedisys (AMED)
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
Neurocrine price target raised to $165 from $160 at Barclays
Neurocrine price target raised by $5 at Barclays, here's why
Analysts Offer Insights on Healthcare Companies: Revance Therapeutics (RVNC) and Neurocrine (NBIX)